Geodon “metabolic advantages” user fee date
Executive Summary
Pfizer expects an FDA decision on its Geodon (ziprasidone) sNDA claiming "metabolic advantages" that would exempt it from a class warning on diabetes risk by mid-November. Pfizer completed the submission Jan. 22, making Nov. 22 the likely user fee date. All other NDA holders of atypical antipsychotics have complied with FDA's September 2003 request to revise labeling to recommend patient glucose monitoring (1"The Pink Sheet" Sept. 22, 2003, p. 20)...
You may also be interested in...
FDA Sides With Lilly; Seeks Class Warning On Antipsychotic Diabetes Risk
The comparative risk for diabetes among atypical antipsychotics needs further research, FDA says in a letter to six manufacturers requesting a diabetes and hyperglycemia warning across the class
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.